期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
S100B protein in the gut:The evidence for enteroglial-sustained intestinal inflammation 被引量:16
1
作者 Carla Cirillo Giovanni Sarnelli +3 位作者 Giuseppe Esposito fabio turco Luca Steardo Rosario Cuomo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第10期1261-1266,共6页
Glial cells in the gut represent the morphological and functional equivalent of astrocytes and microglia in the central nervous system (CNS). In recent years, the role of enteric glial cells (EGCs) has extended fr... Glial cells in the gut represent the morphological and functional equivalent of astrocytes and microglia in the central nervous system (CNS). In recent years, the role of enteric glial cells (EGCs) has extended from that of simple nutritive support for enteric neurons to that of being pivotal participants in the regulation of inflammatory events in the gut. Similar to the CNS astrocytes, the EGCs physiologically express the SIOOB protein that exerts either trophic or toxic effects depending on its concentration in the extracellular milieu. In the CNS, SIOOB overexpression is responsible for the initiation of a gliotic reaction by the release of pro-inflammatory mediators, which may have a deleterious effect on neighboring cells. SlOOB-mediated pro-inflammatory effects are not limited to the brain: SIOOB overexpression is associated with the onset and maintenance of inflammation in the human gut too. In this review we describe the major features of EGCs and SIOOB protein occurring in intestinal inflammation deriving from such. 展开更多
关键词 Enteric glial cells Nitric oxide INTESTINALDISEASES
下载PDF
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy
2
作者 fabio turco Marcello Tucci +9 位作者 Marco Donatello Delcuratolo Rosario Francesco Di Stefano Chiara Pisano Alessandro Audisio Marco Audisio Antonio Ungaro Cinzia Ortega Massimo Di Maio Giorgio Vittorio Scagliotti Consuelo Buttigliero 《Cancer Communications》 SCIE 2022年第8期683-688,共6页
1|BACKGROUND Since 2004,the treatment landscape of metastatic prostate cancer(mPC)has significantly changed.When added to androgen deprivation therapy(ADT),many treatments demonstrated to improve overall survival(OS)o... 1|BACKGROUND Since 2004,the treatment landscape of metastatic prostate cancer(mPC)has significantly changed.When added to androgen deprivation therapy(ADT),many treatments demonstrated to improve overall survival(OS)of mPC patients both in hormone-sensitive(mHSPC)[1]and castration-resistant(mCRPC)setting[2].With multiple available options,therapy selection and the optimal treatment sequence are currently crucial clinical challenges. 展开更多
关键词 METASTATIC DEPRIVATION CANCER
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部